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doi:10.1016/j.ejvs.2010.10.009Abstract Objectives: Treatment by sclerotherapy has been suggested as a first-line treat-
ment of low-flow vascular malformations. This study reports our experience in treating low-
flow vascular malformations by ultrasound-guided sclerosis with polidocanol foam at the
Vascular Medicine Department in Grenoble, France.
Design: Retrospective single-centre consecutive series.
Materials and methods: Between January 2006 and December 2009, we analysed the complete
records of patients with symptomatic low-flow vascular malformations of venous, lymphatic or
complex type (KlippeleTrenaunay syndrome, KTS) treated by ultrasound-guided sclerosis. The
therapeutic indication was always validated by the Consultative Committee for vascular mal-
formations of the University Hospital of Grenoble. All vascular malformations were classified
according to the Hamburg Classification. The sclerosing agent was polidocanol used as foam.
Results: A total of 24 patients between 7 and 78 years were treated (19 venous malformations,
three KTSs and two venous-lymphatic malformations). The concentrations of polidocanol used
ranged from 0.25% to 3%. The average number of sessions was 2.3 (1e16). After a median
follow-up at 5 months after the last session, 23 out of 24 patients reported a decrease in pain;
in nine cases (37.5%), over 50% reduction in size was observed, and in 14 cases (58.3%), a reduc-
tion of less than 50% of the original size was obtained. Two minor side effects were reported.tions; KTS, KlippeleTrenaunay syndrome; LM, Lymphatic Malformation; NA, Not applicable.
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Sclerotherapy of Vascular Malformations with Polidocanol Foam 413Conclusions: Treatment by ultrasound-guided sclerosis using polidocanol foam seems to be
well tolerated and can improve the symptoms of low-flow malformations without the risks
of more aggressive sclerosing agents, such as ethanol.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.The treatmentof vascularmalformations isunsystematicwith
too little therapeutic evidence. As a result, it is commonly
accepted that the therapeutic strategy should be established
by a multidisciplinary medicalesurgicaleradiological team.
In recent years, ultrasound-guided sclerosis with foam has
been proposed as an alternative treatment for low-flow
malformations, especially when surgery cannot achieve
a complete resection or seems too damaging. Among the
available sclerosant products, polidocanol has less sclerosant
power than ethanol but is better tolerated. The superiority of
the foam form over the liquid form in the treatment of
superficial venous insufficiencyandvenousmalformationshas
been demonstrated recently for several sclerosants.1,2
Objectives of the Study
The main objective of this retrospective single-centre study
was to report the therapeutic efficacy and tolerance of
polidocanol foam in the treatment of symptomatic low-flow
vascular malformations, performed at the Centre for
Vascular Medicine at Grenoble University Hospital.
Materials and Methods
Patients
This retrospective study concerned all patients presenting
low-flow malformation according to the criteria of the
Hamburg classification.3 Patients presented one or more
symptomatic vascular malformations, uniquely or predom-
inantly venous including those combined with lymphatic
malformations or complex cases such as KlippeleTrenaunay
syndrome (KTS), treated by foam ultrasound-guided scle-
rosis at the Grenoble Department of Vascular Medicine from
January 2006 to December 2009. The indication for ultra-
sound-guided sclerosis and the therapeutic strategy were
validated by the Committee for Vascular Malformations of
Grenoble University Hospital, which includes vascular
physicians, dermatologists, vascular surgeons, maxillofacial
surgeons and vascular radiologists and meets quarterly. A
strategy of combined treatment (sclerotherapy and
surgery) could be proposed, with the sclerotherapy being
performed first. A history of previous treatment (emboli-
sation, sclerotherapy or surgery) was not an exclusion
criterion. There was no age limit for inclusion. The indi-
cation for ultrasound-guided sclerosis was rejected in cases
of asymptomatic lesions, the presence of associated arte-
rial malformations, poor treatment compliance and the
existence of a contraindication to ultrasound-guided scle-
rosis (such as a history of thrombo-embolic disease or
known permeable foramen ovale). The pre-therapeutic
evaluation was primarily clinical to clarify the symptoms
(pain, neurological signs and trophic disorder) and the typeand size of the malformation(s). Photographs were taken.
Duplex ultrasonography was routinely performed, often
supplemented with an angio-magnetic resonance imaging
(MRI) or computed tomography (CT) angiography. Clear
information about the ultrasound-guided sclerosis treat-
ment was given to the patient both orally and in writing
(IRB number 5891).
Procedure
The treatment was performed in an outpatient operating
room. The patient’s written consent, or that of the parents of
a juvenile patient, was obtained. At the beginning of each
treatment session, a pretreatment echo-Doppler was carried
out to verify the type, depth and accessibility of the malfor-
mation and to choose the most suitable injection method
(direct puncture, in most cases, or by catheterisation).
Depending on the topography of the malformation and the
patient’s age, local anaesthesia with Emla ointment
(lidocaineþprilocaine)or light general anaesthesiabynitrous
oxide (Kalinox, particularly for children) was performed.
The sclerosing agent used was polidocanol at concen-
trations ranging from 0.25% to 3%, according to the size and
depth of the lesion and the response to previous treatment.
Foam was produced by Tessari’s method, the sclerosing
liquid being diluted with air at a ratio of 1 volume of liquid
sclerosant to 4 volumes of air. Colour Doppler ultrasonog-
raphy was performed with a TurboM SonoSite system with
a high-resolution probe of 7.5 MHz and a superficial probe
of 12 MHz. The patient was supine or prone, according to
the topography of the lesion. First, a syringe or a short
catheter (20 G 22 G butterfly 1.1  48 mm or 0.9  22 mm)
was inserted under ultrasound-guided control. The next
stage was performed under ultrasound-guided control with
sterile gel and gloves. The volume of foam injected was
estimated by the amount necessary to obtain a venous
spasm, but never exceeded 10 ml. Compression by super-
posing an Elastomousse band and Elastoplast tape was
applied immediately after treatment and maintained for 3
days (24/24 h) when the topography permitted (trunk or
limbs). After this, when the malformation was on a limb, an
elastic compression stocking (20e36 mmHg) was worn
during the day for 15 days. A prescription was given for
Hirucre`me and a paracetamol-based (1 g) analgesic in
case of pain, with instructions to rest and to avoid any
sports activity for 10 days. The patient was kept under
surveillance for 2e3 h after the invasive procedure.
Evaluation of Treatment and Follow-up
A clinical and ultrasound examination was performed on
day 8. In cases of repeated procedures, an interval of at
least 4e6 weeks between sessions was observed. The
decision to continue the treatment or not was made with
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of the treatment, patients were followed up in a non-
standardised manner, usually 1e3 months after the last
session. When a consultation was not possible, telephone
contact was made with the patient. Complications were
classified as minor (pain, marked swelling, haematoma,
cutaneous necrosis and superficial thrombosis) or major
(allergic reaction, renal failure, deep vein thrombosis,
pulmonary embolism, thoracic pain and stroke).
Results
The clinical characteristics of the 24 patients treated are
summarised in Table 1. The dose injected per session ranged
from 0.25 to 10 ml and the concentrations from 0.25% to 3%,
depending on the size of the malformation, its depth, the
possible occurrence of a venous spasm and response to
previous treatment. The number of sessions also varied,
depending on clinical and ultrasound responses, and ranged
from1 to 16 (Table 2). Themedian follow-upof patientswas 5
months after the last treatment session. The criteria for
evaluating the effectiveness of treatment were both clinical
(reduction in sizeof the vascularmalformation and reduction
of symptoms) andby ultrasound (% reduction in volumeof the
malformation) (Table 3). No serious adverse effects were
reported, including any thrombo-embolic events, with or
without symptoms. Two minor complications were reported
concerning pigmentations in a KTS patient and in an infil-
trated extra-truncular vascular malformation.
Discussion
Ultrasound-guided sclerosis with polidocanol as a foam is
considered less effective than alcohol or Ethibloc but hasTable 1 Clinical presentation of low-flow venous malformation
Venous malformation
Extra-truncular n Z 18 (%) Complex n
Infiltrating
n Z 12 (%)
Limited
n Z 6 (%)
Baseline
characteristics
Men, n (%) 1 (8.3) 4 (66.6) 1 (100)
Mean age in
years (range)
34.66 (7e78) 30.8 (12e47) 40
Distribution
of the lesions
Head and neck 6 2 0
Trunk 1 0 0
Limbs 5 3 1
Multiple 0 1 0
Size
below 10 cm 2 5 0
above 10 cm 10 1 1
Previous treatment
Medical 2 1 0
Surgical 5 2 0
Endovascular 2 0 0many advantages due to it being well tolerated. This
technique can be performed as an outpatient procedure,
while more powerful sclerosing agents such as alcohol
cannot. Indeed, the procedure requires no anaesthesia. In
some cases, particularly in children, local anaesthesia or
light general anaesthesia with, for example Kalinox, is
performed. Post-intervention surveillance only lasts a few
hours, and is not conditioned by the same requirements as
when general anaesthesia has been used. Furthermore,
additional treatments such as antibiotics or anti-inflam-
matory medication, frequently used when sclerosis is with
alcohol, are rarely needed, although analgesics are often
necessary. Few studies on this topic are available in the
literature and those that are often are only reports of
a small series of case studies. Table 4 summarises the main
publications on ultrasound-guided sclerosis with polidoca-
nol foam of venous malformations and KTS, and illustrates,
as in our study, the few side effects of this technique.
Polidocanol is not as potent as ethanol, but, unfortu-
nately, few studies have directly compared the effective-
ness of the various available sclerosing agents. In our team,
we use polidocanol rather than sodium tetradecyl sulphate,
which seems to have similar sclerosing power according to
our experience in chronic venous insufficiency. However,
there are no studies on this subject either for venous
insufficiency or for low-flow malformations. The lack of
blinded randomised studies is probably because of the
heterogeneity of malformations, and the different treat-
ment strategies used for different types of malformation.
This is the case in the prospective randomised study of
Yamaki et al.,2 where polidocanol was used for superficial
lesions and ethanolamime oleate for deeper lesions, in
liquid versus foam forms. The superficial, or not, aspect of
the lesion conditioned the choice of sclerosant, preventing
blinding. Nevertheless, they showed improved efficiency ofs.
Combined malformations Total n Z 24 (%)
Z 1 (%) KTS n Z 3 (%) LM n Z 2(%)
3 (100) 2 (100) 11 (46)
34 (26e36) 28 (19e37) 33.6 (7e78)
0 1 9
0 0 1
3 1 13
0 0 1
NA 1 8
NA 1 13
2 0 5
0 1 8
1 0 3
Table 2 Details of the percutaneous sclerotherapy procedures in patients with low-flow malformations.
Venous malformation Combined malformations Total (n Z 24)
Infiltrating (%) Limited (%) Complex (%) KTS LM
Number of sclerotherapy
sessions with polidocanol:
1 2 (16.7) 1 (16.7) 1 (100) 3 (100) 1 (50) 8 (33.3)
2 5 (41.7) 4 (66.6) 0 (0) 0 (0) 1 (50) 10 (41.7)
more than 2 5 (41.7) 1 (16.7) 0 (0) 0 (0) 0 (0) 6 (25)
Mean dose of polidocanol
injected (ml/session)
2.7 2 6 10 4.7 5.5
Mean total dose of polidocanol
injected (ml/patient)
16.4 4.4 6 31.7 4.7 13.5
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vascular malformations in both nature and topography
makes it difficult to assess the therapeutic efficacy of these
techniques, as does the use of different classification
systems for malformations.
Due to the small number of malformations treated at our
centre, we chose to include KTSs that strongly resemble
venous malformations but, strictly speaking, are syndromic
forms and not exclusively venous malformations. In our
clinical practice, the decision as to the treatment strategy
to use is based primarily on the symptomatic character of
the malformation and is made with goals fixed in consul-
tation with the patient. The therapeutic decision is based
on subjective criteria that are sometimes difficult to eval-
uate. Thus, an improvement in symptoms may lead to
discontinuation of therapy sessions, even when the clinical
appearance or ultrasound shows no regression in size of the
malformation. Our study is nonetheless informative on the
choice of concentrations and quantities of sclerosant
injected and shows a better therapeutic effect with high
concentrations, without increased complications. This
notion is not necessarily found in studies of polidocanol
foam in chronic venous insufficiency.4 One issue that has
been raised is the maximum quantity of sclerosing agent
that can be used at the highest concentration of 3%. In the
treatment of venous insufficiency, the consensus report ofTable 3 Clinical and ultrasound evaluation of sclerotherapy wi
Venous malformation
Infiltrating (%) Limited (
Mean duration of follow-up (months) 17 6.5
Ultrasound result
Sclerose greater than 50% 5 (41.7) 3 (50)
Sclerose smaller than 50% 7 (58.3) 3 (50)
Stable 0 (0) 0 (0)
Worsened 0 (0) 0 (0)
Recanalized 2 (16.7) 0 (0)
Effect on pain
Decrease 12 (100) 4 (100)
Stable 0 (0) 0 (0)
Recurrence 3 (25) 1 (25)
Effect on others symptoms
Decrease 2 (100) 1 (100)
Stable 0 (0) 0 (0)Tegernsee recommended maximum doses of 6e8 ml for
ultrasound-guided sclerosis of the great saphenous vein
treated with foam and 3 ml for a small saphenous vein with
concentrations usually of 0.5e1%.5 The treated vascular
malformations vary in volume, and this is often difficult to
estimate, but is well above the volume of the large or small
saphenous veins. Some authors use a maximum dose of
10 ml with 3% foam,6 while others use up to 1 ml kg1 at
1%.2 Our attitude was conservative and injections never
exceeded 10 ml per session. The methodological limitations
of our retrospective study did not allow us to assess the
prognostic factors, but the results are consistent with
efficacy for well-circumscribed vascular malformations of
less than 10 cm in diameter due to a better length of
contact between the sclerosant and the vascular walls, as
already described by some authors.6 The lower efficiency in
large malformations could be explained by a shorter
contact time between the sclerosing agent and the vascular
walls. For truncular venous malformations, the faster
diffusion of the sclerosing agent into the bloodstream
seems to make the treatment less effective.
While it is difficult to establish a clear strategic proce-
dure, the technique is nevertheless refined as the operators
gain experience. Initially, the concentrations used were
low. There were probably few side effects, but a loss of
efficacy. The strategy was therefore modified to use higherth polidocanol foam.
Combined malformation (%) Total (%)
%) Complex (%) KTS LM
1 19.5 2 9.5
0 (0) 1 (33.3) 0 (0) 9 (37.5)
1 (100) 2 (66.6) 1 (50) 14 (58.3)
0 (0) 0 (0) 1 (50) 1 (4.2)
0 (0) 0 (0) 0 (0) 0 (0)
1 (100) 1 (33.3) 0 (0) 4 (16.7)
1 (100) 3 (100) 1 (50) 21 (95.5)
0 (0) 0 (0) 1 (50) 1 (4.5)
0 (0) 1 (33.3) 0 (0) 5 (22.7)
NA 1 (50) 1 (100) 5 (83.3)
NA 1 (50) 0 (0) 1 (16.7)
Table 4 Review of the literature on treatments by sclerotherapy with polidocanol foam.
Authors Number
of cases
Type
of MV
Site Treatment Results Complications
Yamaki et al7 1 VM Face Polidocanol 1% 5 cc foam Reduction in size 0
Cabrera et al8 50 19 VM limited
16 VM infiltrated
15 KTS
Polidocanol foam 0.25e4% 6 ml
max 1 to 46 sessions (12)
Reduction in size 92%
Reduction in
pain in 14 cases.
Disappearance of
pain in 25 cases.
4 pigmentations
3 skin necrosis
Pascarella et al9 11 8 KTS
3 VM
Limb Polidocanol
foam 1e3% 1-cc 3.6 sessions
10 cosmetic improvement 1 wound
Bergan et al10 12 9 KTS
3 VM
Limb Polidocanol foam 1e3% 11 Reduction in size, pain
and cosmetic improvement
1 wound
Nitecki et al11 7 KTS Polidocanol 2e4% Sessions
9e21 (14.5)
Reduction in symptoms 2 regressive
pigmentations
1 superficial
thrombosis
Bergan et al12 14 8 KTS
12 Extra trunk
2 combined extra
trunk and trunk
3 wounds Polidocanol foam 1e2% 3.6
sessions (1e10)
1 cutaneous ulcer
Mimura et al6 31 VM Face, trunk
and members
Polidocanol foam 3% 5 ml Reduction in pain Hypotension
Bradycardia
Avulsion of nail
Follow-up of 46 months
Uehara et al13 7 VM Head and neck,
trunk and foot
Polidocanol foam 3% Sessions
(2e13)
Reduction in symptoms Œdema and/or pain in 55%
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Figure 1 Facial Venous Malformation before (a) and after (b) combined treatment by sclerotherapy with polidocanol foam and
surgery.
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gressing rapidly to 3%), except when the lesions had
a significant cutaneous component.
The volume injected must be adjusted to the volume of
each malformation, with the goal of obtaining the longest
possible contact time between the agent and the vascular
walls, with, for example, the help of ultrasound-guided
manual compression. A randomised study would be difficult
or impossible to implement in view of the strategic choices
necessary to obtain an optimal result, as, in some cases,
combined treatment by foam ultrasound-guided sclerosis
and, then, surgery is needed (Fig. 1).
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